Current et al. demonstrated that PC-3 PIP xenografts with higher ratios of PSMA-positive to PSMA-negative cells resulted in higher tumor uptake and therapeutic efficacy of 177Lu- and 225Ac-labeled PSMA-617 [36]. The gene discussed is FOLH1; the disease is neoplasm.